HRT Financial’s Co-Diagnostics CODX Stock Holding History

HRT Financial’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32K	Buy	+30,355	New	+$48.6K	﹤0.01%	4415
2025 Q4	–	Sell	-4,976	Closed	-$51K	–	3281
2025 Q3	$51K	Buy	4,976 +4,533	+1,023%	+$42.2K	﹤0.01%	2602
2025 Q2	$3K	Sell	443 -32	-7%	-$299	﹤0.01%	2494
2025 Q1	$4K	Buy	+475	New	+$9.08K	﹤0.01%	2412
2023 Q2	–	Sell	-417	Closed	-$18K	–	2576
2023 Q1	$18K	Buy	417 +21	+5%	+$1.68K	﹤0.01%	2190
2022 Q4	$29K	Buy	+396	New	+$37.1K	﹤0.01%	2146
2022 Q1	–	Sell	-947	Closed	-$253K	–	3208
2021 Q4	$253K	Sell	947 -764	-45%	-$200K	﹤0.01%	2375
2021 Q3	$499K	Sell	1,711 -864	-34%	-$252K	﹤0.01%	1981
2021 Q2	$637K	Buy	+2,575	New	+$662K	0.01%	1556

Other funds holding CODX

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Private Advisory Group Redmond, Washington $1.87B AUM 37.58% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

HRT Financial's CODX Position: Q3 2026 in Review

HRT Financial opened a new position in Co-Diagnostics (CODX) in Q3 2026: 30,355 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #4415 among its holdings. This is a return to the name: HRT Financial previously reported a position in CODX as recently as Q3 2025.

HRT Financial first reported a position in CODX in Q2 2021 and has held it in 9 quarters since. The position peaked at $637K in Q2 2021. 20 funds tracked by Wall St. Rank hold CODX as of Q3 2026.

HRT Financial held 30,355 shares of Co-Diagnostics worth $32K as of Q3 2026.
Co-Diagnostics was a new HRT Financial position in Q3 2026.
Co-Diagnostics made up ﹤0.01% of HRT Financial's portfolio in Q3 2026, its #4415 holding.
HRT Financial first reported a position in Co-Diagnostics in Q2 2021 and has held it in 9 quarters since.
HRT Financial's Co-Diagnostics position peaked at $637K in Q2 2021.
20 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.